| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chocolate made from roasted and ground cocoa beans. Chocolate — chocolate is a cocoa-derived food matrix made from processed beans of Theobroma cacao and contains variable amounts of flavan-3-ols (especially epicatechin/catechin and procyanidins), methylxanthines such as theobromine, fats, and sugars depending on formulation. In the cancer-context it is best classified as a dietary polyphenol-rich natural product / food exposure rather than a standardized drug. Mechanistically relevant subcomponents are usually discussed as cocoa flavanols, epicatechin, procyanidins, and theobromine. The source is cacao bean fermentation, roasting, grinding, and formulation into cocoa powder or chocolate. Mechanistic interpretation is formulation-dependent: dark chocolate / cocoa extracts are the most relevant for bioactive flavanol content, whereas milk chocolate and high-sugar products are much less useful as mechanistic proxies. Primary mechanisms (ranked):
Bioavailability / PK relevance: Cocoa bioactivity is driven mainly by absorbable monomeric flavanols, especially epicatechin metabolites, while larger procyanidins have limited direct systemic absorption and likely act more through gut/luminal processing. Theobromine is well absorbed and persists longer systemically than flavanols. Delivery is therefore food-matrix dependent, and cocoa extract or high-flavanol cocoa is mechanistically more relevant than ordinary confectionery chocolate. In-vitro vs systemic exposure relevance: This is a major constraint. Many in-vitro anticancer studies use cocoa extracts or epicatechin concentrations above typical circulating levels achievable from ordinary chocolate intake. Human exposure after cocoa intake clearly yields circulating epicatechin metabolites, but common cell-culture doses often exceed realistic plasma levels, so direct cytotoxic interpretation should be cautious. Adjunct vascular, inflammatory, or signaling effects are more clinically plausible than standalone antitumor cytotoxicity from dietary chocolate. Clinical evidence status: Preclinical anticancer evidence is moderate, spread across cell and some animal models, with supportive but heterogeneous mechanistic literature. Human oncology evidence is weak. There is no established anticancer therapeutic role for chocolate itself, and oncology trial activity is limited; available human work is largely non-cancer cardiometabolic/cognitive supplementation research, plus a small palliative-care study of chocolate intake rather than tumor-control efficacy. Mechanistic overview
P: 0–30 min |
| Source: |
| Type: |
| The relationship between LDL (low-density lipoprotein) cholesterol and cancer is a complex and evolving area of research. LDL cholesterol is often referred to as "bad" cholesterol because high levels are associated with an increased risk of cardiovascular diseases. Protumorigenic: High levels of LDL cholesterol can promote tumor growth by providing lipids that are essential for cell membrane synthesis and energy production. Additionally, LDL can influence inflammation and angiogenesis, further supporting tumor development. Antitumorigenic: Some studies suggest that lowering LDL cholesterol through lifestyle changes or medications (like statins) may have a protective effect against certain cancers, although the evidence is not uniform across all cancer types. |
| 6086- | CHOC, | Cocoa and Chocolate in Human Health and Disease |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:60 Target#:71 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid